Abstract
Introduction The COVID-19 pandemic has accentuated a health-wealth gradient, reminiscent of patterns observed in previous influenza pandemics. This systematic review, employing a population-based approach, aims to delve into the etiological and prognostic roles of socio-economic factors on COVID-19 outcomes during the pandemic’s initial phase.
Methods Our search spanned PubMed, Embase, WHO COVID-19 Global literature, and PsycINFO databases from January 2020 to April 7, 2021, focusing on English peer-reviewed articles. We examined the impact of socio-economic determinants on SARS-CoV-2 infection, COVID-19 related hospitalization, ICU admission, mechanical ventilation, mortality, and a range of prognostic outcomes including quality of life and mental health.
Results The initial search resulted in 9,701 records after removal of duplicates. Out of hundred articles that met our review criteria, 67 discussed the etiological role of socio-economic factors, 25 addressed the prognostic role, and 8 covered both. Fifty-nine percent of the studies were from the United States of America and the United Kingdom, highlighting an increased risk of infection and severity among their Black, Asian, and Hispanic populations. Lower-income groups, crowded households, and, higher socio-economic deprivation were associated with higher COVID-19 incidence and severity. Results regarding educational status varied across different waves.
Conclusion Populations groups with disadvantaged socio-economic positions and certain ethnic and racial backgrounds face a higher risk of SARS-CoV-2 infection and poorer COVID-19 outcomes. Our findings underscore the need for incorporating social determinants into routine health surveillance and monitoring, suggesting an avenue for targeted interventions.
What is already known on this topic The association between socio-economic factors and outcomes, observed during the COVID-19 pandemic and other influenza epidemics, indicates a significant health-wealth gradient. Higher mortality and worse health outcomes are observed in the most disadvantaged groups of the population
What this study adds This study lays out a comprehensive review of population-based studies, representative of the general population, on the etiological and prognostic role of socio-economic characteristics in COVID-19 outcomes covering studies across 22 countries. Our results show that population-based studies from countries in Asia, Africa, Latin America, and continental Europe were limited in the early phase of the pandemic and highlight the importance of socio-economic characteristics, alongside comorbidities, for predicting SARS-CoV-2 infection and COVID-19 severity.
How this study might affect research, practice or policy This evidence shows a gap in the literature in countries other than the USA and the UK and on the role of socio-economic characteristics in long-term COVID-19 outcomes. Social inequalities need to be at the heart of infectious disease monitoring and surveillance to decrease the gap in adverse outcomes between patients of different socio-economic profiles.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/36414309/
Funding Statement
The study has been completed within the Population Health Information Research Infrastructure (PHIRI) project. PHIRI is funded by the European Union(EU)- Horizon 2020 research and innovation program (Grant agreement No: 101018317 https://cordis.europa.eu/project/id/101018317/fr).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.